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Abstract: Vascular aging plays a central role in health problems and mortality in older people. Apart
from the impact of several classical cardiovascular risk factors on the vasculature, chronological
aging remains the single most important determinant of cardiovascular problems. The causative
mechanisms by which chronological aging mediates its impact, independently from classical risk
factors, remain to be elucidated. In recent years evidence has accumulated that unrepaired DNA
damage may play an important role. Observations in animal models and in humans indicate that
under conditions during which DNA damage accumulates in an accelerated rate, functional decline
of the vasculature takes place in a similar but more rapid or more exaggerated way than occurs in
the absence of such conditions. Also epidemiological studies suggest a relationship between DNA
maintenance and age-related cardiovascular disease. Accordingly, mouse models of defective DNA
repair are means to study the mechanisms involved in biological aging of the vasculature. We here
review the evidence of the role of DNA damage in vascular aging, and present mechanisms by which
genomic instability interferes with regulation of the vascular tone. In addition, we present potential
remedies against vascular aging induced by genomic instability. Central to this review is the role
of diverse types of DNA damage (telomeric, non-telomeric and mitochondrial), of cellular changes
(apoptosis, senescence, autophagy), mediators of senescence and cell growth (plasminogen activator
inhibitor-1 (PAI-1), cyclin-dependent kinase inhibitors, senescence-associated secretory phenotype
(SASP)/senescence-messaging secretome (SMS), insulin and insulin-like growth factor 1 (IGF-1)
signaling), the adenosine monophosphate-activated protein kinase (AMPK)-mammalian target of
rapamycin (mTOR)-nuclear factor kappa B (NFκB) axis, reactive oxygen species (ROS) vs. endothelial
nitric oxide synthase (eNOS)-cyclic guanosine monophosphate (cGMP) signaling, phosphodiesterase
(PDE) 1 and 5, transcription factor NF-E2-related factor-2 (Nrf2), and diet restriction.
Keywords: vascular; aging; endothelium; genomic instability; DNA damage; senescence; PAI-1;
eNOS; phosphodiesterase; dietary restriction
1. Introduction
Cardiovascular diseases (CVD) are the leading cause of death worldwide, responsible for
killing 17.3 million persons per year [1]. The onset of CVD is triggered by vascular endothelial
alterations characterized by an impaired endothelium-dependent vasodilation, the overproduction
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of pro-inflammatory and prothrombotic molecules, and oxidative stress [2]. Age is the strongest
independent predictor for CVD in risk scores in middle-aged persons, and an important determinant
for cardiovascular health in the population aged 65 or older [3,4]. Aging is characterized by the
complex interaction of cellular and molecular mechanisms that leads to a collection of functional
problems. Focusing on the vasculature, such problems are closely associated with each other, and
include worsened vasodilation, increased arterial stiffness and overt remodeling of the extracellular
matrix, diffuse intimal thickening and a dysfunctional endothelium [4]. The mechanisms through
which age actually contributes to cardiovascular risk remain the subject of speculation. From a
classical perspective, modifiable risk factors promote and modulate molecular mechanisms that, as
time progresses, culminate in an imbalance in the production vs. scavenging of ROS (i.e., superoxide
anions, hydrogen peroxide and hydroxyl radicals), increasing ROS levels, and, as a consequence,
reducing the bioavailability of nitric oxide (NO) [5,6]. NO is crucial in the maintenance of vascular
homeostasis, including in the regulation of vascular dilation, the modulation of cell growth and the
prevention of thrombosis [7]. In the absence of a healthy endothelium, these factors gradually increase
the pathologic phenotype of the vasculature up to the point that cardiovascular events occur.
While this paradigm explains vascular aging in view of classical risk factors as causative
mechanisms, a recently proposed alternative view on vascular aging has emerged that presents new
mechanistic alternatives for understanding the process of vascular aging [8]. In this novel paradigm,
causal mechanisms for the process of aging itself, most notably genomic instability, including telomere
attrition, drive the detrimental changes occurring increasingly with (biological) aging (Figure 1).
The involvement of these causal factors of aging in general have been discussed elsewhere [9]. In the
present review we summarize the evidence that supports the role of genomic instability in vascular
aging. In addition, we present mechanisms through which genomic instability generates the functional
changes that are typical for the aging vasculature.
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Figure 1. Etiology of vascular aging based on genomic instability as a causal factor. Classical and 
unidentified risk factors contribute to various types of DNA lesions. Unrepaired lesions 
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have beneficial (increased Nrf2-regulated antioxidants) as well as detrimental (decreased IGF-1 
signaling, pro-inflammatory status) effects (see text and Ref. [8]). 
Figure 1. Etiology of vascular aging based on genomic instability as a causal factor. Classical and
unidentified risk factors contribute to various types of DNA lesions. Unrepaired lesions accumulating
during life lead to a growing set of pathophysiological changes that, either independently or in
mutual interaction, lead to progressive vascular aging. The putative role of transcriptional problems
or mutations herein needs to be established. The survival response may have beneficial (increased
Nrf2-regulated antioxidants) as well as detrimental (decreased IGF-1 signaling, pro-inflammatory
status) effects (see text and Ref. [8]).
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2. Genomic Instability and Aging: A Short Outline of the Basic Principles
2.1. DNA Repair Systems
The maintenance of genomic integrity is critical for the prevention of aging of organisms.
To safeguard genomic integrity, cells are equipped with several genomic maintenance systems
that sense and repair DNA damage [10,11]. The sources of DNA damage are very diverse and
range from intrinsic molecular reactions within DNA molecules such as hydrolysis, attacks by
endogenous metabolic products, and ROS, to damage by exogenous physical and chemical entities
such as chemotherapy and UVB light [12]. To account for the different types of DNA damage,
cells are equipped with multiple DNA repair pathways. Each repair system is responsible for a
specific subset of lesions, although partial overlap can occur depending on the type of DNA lesion
that needs to be repaired. At least six DNA repair pathways can be listed in mammalian cells:
(1) the direct reversal pathway, which executes the direct reversal of chemical modifications of
nucleotides; (2) mismatch repair (MMR), which repairs base pair mismatches; (3) base excision repair
(BER), repairing mainly oxidized and alkylation lesions in the nucleus and mitochondria, as well as
single-strand breaks; (4) nucleotide excision repair (NER), to correct transcription-disturbing bulky
adducts; (5) homologous recombination (HR); and (6) non-homologous end joining (NHEJ), which
correct single- and double-strand breaks [10,13]. Telomere maintenance requires further specialized
proteins [14]. Hypothetically, the classical cardiovascular risk factors initiate ROS-induced DNA
damage and thus contribute to genomic instability-related vascular aging (Figure 1). Although some
factors that lead to (vascular) genomic instability have been identified, the road to identification of all
relevant contributors is still long (Figure 1) [8,15].
2.2. Aging: The Interplay between Genomic Damage, the Survival Response and Cellular Senescence
Unrepaired genomic damage enables the generation of harmful mutations that can be transferred
to new cells during proliferation. This puts complex organisms at the potential risk of rapidly
developing dysfunctional tissues or even tumors. As a protective measure, accumulating unrepaired
DNA damage triggers a switch in biological pathways from a phenotype supporting growth to one
favoring maintenance of the organism, a switch often referred to as the “survival response” [16].
However, the switch is believed to contribute to the typical changes that occur during aging,
as demonstrated in humans and animals with defective DNA maintenance [16].
To avoid the harmful consequences of genomic instability, such as cancer, complex organisms
have developed protective cellular mechanisms, namely apoptosis and cellular senescence. Whereas
apoptosis embodies the loss of (dysfunctional) tissue due to programmed cell death, which might
account for loss of organ function, cellular senescence has a more intricate relationship with aging
tissues. Senescent cells undergo cell cycle arrest and thus can no longer replicate, although they
remain metabolically active and often acquire a SASP, an immunogenic phenotype consisting of
interleukins, pro-inflammatory cytokines, and growth factors [17]. It is believed that this results in an
increased susceptibility to age-associated disease, including cancer and cardiovascular disease [17].
As a consequence of cellular senescence, the organisms age and become susceptible to age-associated
diseases. Paradoxically, the accumulation of senescent cells with age, which is believed to result from
an inefficient clearance by the immune system, might also help delay tissue dysfunction through cell
loss. Recently, however, it was shown that removal of senescent cells expressing the cyclin-dependent
kinase inhibitor p16INK4A in genetically modified mice (INK-ATTAC mice) leads to a prolonged life
and health span [18], supporting a fundamental role for cellular senescence in aging. The mechanisms
through which removal of senescent cells leads to these effects remain to be elucidated.
3. Genomic Instability as a Causal Factor in Vascular Aging: Evidence in Humans
There is ample evidence that genomic instability is involved in vascular aging in humans.
The following section highlights the observations that have accumulated until the present.
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3.1. Cardiovascular Disease in Progeria Syndromes
The role of DNA damage in aging is further highlighted in human progeria syndromes. Human
syndromes of progeria arise from mutations in genes involved in genomic maintenance in at least
75% of the known cases [19]. Progeria syndromes provide a unique opportunity to study aging, but it
should be noted that they are not a complete phenocopy, e.g., progeria patients show phenotypes that
are rare during normal aging, such as clavicular agenesis in Hutchinson-Gilford progeria syndrome
or the intensified risk of cancer in Werner syndrome [20]. The relation of progeria to normal aging
remains debatable.
Despite this continuing debate, it is intriguing to observe that several progeria syndromes manifest
severe, juvenile cardiovascular disease. Werner syndrome (WS) is characterized by the premature
onset of clinical signs of aging, such as cancer, osteoporosis and cardiovascular disease (diabetes
mellitus type II and atherosclerosis) [21]. WS is caused by a WRN (Werner) gene mutation. WRN
encodes a DNA helicase protein, Escherichia coli recQ-like helicase L2 (RECQL2), which is involved
in DNA recombination, replication, repair and transcription, and also in telomere maintenance [22].
WS patients develop a considerable burden of atherosclerotic plaques in the coronary arteries and the
aorta; calcification of the aortic valve is also frequently observed. Consequently, most WS patients die
during middle age (average life expectancy is 46 years) due to myocardial infarction and stroke [21].
A related disease called Bloom syndrome, a consequence of mutation of the RecQ helicase gene BLM,
features telangiectasias (dilated blood vessels in the skin), but the function of blood vessels has not been
extensively investigated, although the occurrence of diabetes in these patients might be an important
confounder in such investigations [23].
Hutchinson-Gilford progeria syndrome (HGPS), perhaps the best-known progeroid disorder, is
characterized by hair loss, pain in the joints, wrinkled skin, and cardiovascular problems [24]. HGPS is
caused, in most patients, by a point mutation in the lamin A gene (LMNA), which encodes the A-type
nuclear lamins. The mutant lamin A, called progerin, remains fixed to the nuclear envelope causing
various cellular changes, such as irregular nuclear shape and disorganization of heterochromatin,
that lead to abnormal regulation of gene expression, therefore inducing premature aging. Death
occurs around the age of 13 years mostly due to myocardial infarction or cerebrovascular events;
however, in contrast to typical human aging or WS, atherosclerosis is very rare. Instead a major loss of
vascular smooth muscle cells (VSMCs) in both big and small arteries is observed [25]. Interestingly,
accumulation of prelamin A was observed in medial VSMCs and in atherosclerotic lesions from
normally aged individuals. Moreover, prelamin A colocalized with β-galactosidase-positive VSMCs,
i.e., senescent VSMCs, and thus prelamin A was proposed as a marker of vascular aging in the general
population [26].
Excision repair cross-complementation group 1 (ERCC1)-xeroderma pigmentosum (XP) F is
a structure-specific protein complex serving as an endonuclease that participates in the repair of
several types of DNA lesions, mainly bulky, helix-distorting lesions that are repaired by the NER
pathway, but also double-strand breaks and interstrand cross-links [27–29]. Progeroid syndromes
arising from ERCC1-XPF mutations, often unique cases as each of the mutations found until now has
been encountered in individual patients, have been repeatedly reported as being characterized by
hypertension [30]. This is further accompanied by frailty, loss of subcutaneous fat, liver dysfunction,
vision and hearing loss, renal insufficiency, bone marrow degeneration, and kyphosis [31]. Although
the hypertension observed in this syndrome might point at accelerated vascular aging, this still needs
to be confirmed, certainly if one takes into consideration the presence of renal insufficiency in the
patients suffering from this type of syndrome.
For other progeroid syndromes related to mutations in genomic DNA repair enzymes, data
concerning vascular function are not available. It is uncertain whether this is an indication for the
absence of vascular aging. Rather, more prominent problems in other organ systems or a focus on
increased susceptibility to cancer might mask the presence of cardiovascular problems. In general, the
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patients are very frail, and cases are rare. Extensive cardiovascular characterization of such patients is,
therefore, a very challenging task, and perhaps even not without risk for the patients themselves.
3.2. Indicators of a Role of Genomic Instability in the General Population
The role of genomic instability in disorders of the vasculature or the consequences thereof is a
question that becomes increasingly important for the general population. If, indeed, this mechanism is
central in age-related cardiovascular disease, there are major implications for prediction and detection
and prevention. Research on the role of genomic instability in cardiovascular risk prediction opens a
new window into expanding our understanding of the pathophysiology and causative risk factors
in age-related diseases [8]. The use of emerging markers of DNA damage, identified in vascular
and cardiac ischemic cells, has provided evidence for this role [32]. Part of the evidence comes from
studies assessing the effect of ionizing radiation. An increased amount of circulating cell-free DNA
and mitochondrial DNA (mtDNA) fragments has been observed in subjects exposed to low levels of
ionizing radiation, suggesting the possible role of circulating DNA as a relevant biomarker of cellular
damage [33]. In turn, it has been established that there is an association between radiation exposure
and indicators of accelerated vascular aging, coronary artery disease and stroke in occupationally
exposed groups. Andreassi et al. observed that long-term, low level radiation exposure is positively
correlated to early atherosclerosis, as identified by increased subclinical cIMT (carotid intima media
thickness), and to telomere shortening, an indicator for genomic instability [34]. This study also
concluded that subjects with the Thr241Met polymorphism in the XRCC3 gene (gene coding for X-ray
repair cross-complementing protein 3) have a greater susceptibility to radiation-induced vascular
effects. Data of the Life Span study showed that people who had received an acute single dose of
1–2 Sv (sievert) had a significantly increased risk of mortality from myocardial infarction after 40 years
of radiation exposure [35]. Other evidence is provided by observation of DNA damage markers
in vascular tissue and circulating cells. Several groups observed elevated levels of oxidative DNA
damage in human atherosclerotic plaques compared to non-atherosclerotic vessels or in circulating
cells of persons with arterial disease [36,37]. Likewise, several proteins involved in DNA repair
including DNA-dependent protein kinase (DNA-PK), poly (ADP-ribose) polymerase 1 (PARP-1),
p53, and Apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE-1/Ref1), were up-regulated in
plaques of carotid endarterectomy specimens compared with non-atherosclerotic arteries [36]. On the
other hand, genetic association studies have shown a significant association of single nucleotide
polymorphisms (SNPs) in NER-related genes with age-related vascular phenotypes. In the population
of the AortaGen Consortium, comprising 20,634 participants from nine cohort studies, Durik et al.
identified an association of the SNP rs2029298 (p-value: 1.04 ˆ 10´4) in the Damage-Specific DNA
Binding Protein 2 (DDB2) gene with carotid-femoral pulse wave velocity, a measure of vascular
stiffness [38]. In addition, suggestive associations were found for eight SNPs located within or
near ERCC5, ERCC6, general transcription factor IIH (GTF2H) subunit 1 and 3 (GTF2H3, GTF2H1),
and ERCC2 [38]. Verschuren et al. showed, in data from the GENDER (GENetic DEterminants
of Restenosis) and PROSPER (Patient-centered Research Into Outcomes Stroke Patients Prefer and
Effectiveness Research) studies comprising 6110 coronary artery disease (CAD) patients in total, that
genetic variations in the NHEJ repair system are associated with risk for CAD [39]. In addition, several
smaller studies have shown associations between polymorphisms in single DNA repair genes and
risk of coronary artery disease, as reviewed elsewhere [40]. Interesting to note is also the finding that
statins were found to improve DNA damage detection, which might be a mechanism leading to the
improvement of atherosclerosis next to the reduction of lipids and oxidative stress [41,42].
3.3. Telomere Shortening
Human chromosomes are normally capped by telomeres that protect the end-segment of
chromosomes between cell divisions. Since telomeres do not fully replicate during mitosis, they
gradually become shorter as individuals age [43]. Defects in telomerase activity, abnormalities in DNA
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polymerase to synthesize terminal ends of the DNA, and the inhibition of the sheltering component
telomeric repeat-binding factor 2 (TRF2) leads to an accelerated velocity of telomere shortening between
cell divisions, which induces cellular senescence when the telomere reaches a critical length [43].
Telomere shortening promotes chromosome end fusion, chromosomal abnormalities and aneuploidy,
suggesting that loss of chromosome end protection is correlated to genome instability [44]. Studies
using knockout mouse models have established that the targeted deletion of 53BP1 and TRF2 genes
is one of the main mechanisms involved in double-strand breaks and an increase of non-reciprocal
translocations caused by telomere shortening [45]. In addition, RNA template of telomerase (TERC)´/´
and high mobility group box 1 (HMGB1)´/´ mice exhibit a reduced/null telomerase activity
and telomere dysfunction, triggering aging-like cellular changes [46,47]. Population-based studies
suggest that telomere shortening plays a role in the onset of vascular aging-related phenotypes.
Individuals with a shorter mean telomere length exhibit a two-fold risk of abdominal aortic aneurysm
compared to those with a higher telomere length (odds ratio = 2.30, p = 0.005) [48,49]. Moreover,
an association between telomere shortening and the following CVD risk factors has been found:
atherosclerosis, arterial stiffness (as measured by carotid-femoral pulse wave velocity), smoking,
insulin resistance, type 1 and type 2 diabetes, obesity, hypertension and up-regulation of the
renin–angiotensin–aldosterone system [50–57]. Likewise, an increased level of telomere shortening,
via increased oxidative DNA damage, has been identified in circulating endothelial progenitor cells
(EPC) in CAD patients with metabolic syndrome [58]. These observations suggest that oxidative
stress-induced telomere shortening in EPC may accelerate vascular dysfunction, promoting the onset
and progression of CAD due to a lack of vascular repair [58]. Despite the fact that the association of
telomere shortening with aging and vascular-related disorders has been demonstrated, its potential
use as a biomarker of age-related diseases remains unclear [59–61].
3.4. Cellular Senescence and Its Regulators
The Role of Senescent Cells and Plasminogen Activator Inhibitor-1 (PAI-1)-Related Signaling Pathways
in Vascular Aging
As mentioned previously, genomic instability causes increased cellular senescence, which
is an important candidate mechanism bridging the gap between DNA damage and vascular
aging [8]. Senescent cells and tissues exhibit a distinctive pattern of protein expression, including
increased plasminogen activator inhibitor-1 (PAI-1) as a part of the senescence-associated secretome
(Figure 2) [62]. In addition to contributing to the molecular fingerprint of senescence, PAI-1 is essential
and even sufficient for the induction of replicative senescence in vitro and is a critical downstream target
of the tumor-suppressor p53 [63,64]. The contribution of PAI-1 to cellular senescence is broadly relevant
in the organism as a whole, and age-dependent increases in plasma PAI-1 levels have been identified
in wild-type mice as they age, in murine models of accelerated aging (Klotho and BubR1H/H), and in
humans [18,65,66]. Partial and complete PAI-1 deficiency in Klotho-deficient animals (kl/kl) prevents
telomere shortening and extends median survival up to 4.2-fold with substantial protection against
aging-like phenotypes in various organs [67]. Furthermore, both genetic as well as pharmacological
inhibition of PAI-1 protects against development of aortic arteriosclerosis in mice treated with long-term
nitric oxide synthase inhibition [68].
Metabolism also plays a fundamental role in the biology of (vascular) aging and iIGF1 are widely
endorsed as critical contributors to senescence and aging in several experimental models (e.g., flies,
worms, and mammals) [69]. In observational human studies, PAI-1 levels were increased in obesity
and insulin resistance and independently predicted the future development of type 2 diabetes mellitus
(T2DM) [70,71]. Potential anti-aging interventions have focused on caloric restriction and on drugs with
metabolic effects, including metformin and resveratrol, all of which reduce PAI-1 expression [72–75].
Conversely, PAI-1 production is enhanced by insulin, free fatty acids, and glucose [76–78]. Taken
together, these data suggest that PAI-1 and insulin exhibit a coordinated regulatory reciprocity, and in
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this context PAI-1 represents a high-yield translational target linking metabolism and biological aging,
including aging of the vasculature (Figures 2 and 3).Int. J. Mol. Sci. 2016, 17, 745 7 of 25 
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Figure 2. Molecular effectors of genomic instability that contribute to vascular aging, and the potential
remedies (center of the chart) against that currently under development. Senescence, imbalanced NO
vs. ROS production, inflammation and changes in insulin signaling are detrimental when present
while autophagy, apoptosis and stress resistance have a beneficial contribution to vascular aging. IGF-1
putatively has a detrimental effect, although this needs further scrutiny (Ref. [8]). Pointed arrows
indicate stimulatory processes, while blunted arrows indicate inhibitory processes.
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eNOS-cGMP signaling. PDE1 subtype inhibitor and g anylyl cyclase (GC) stimulat rs are promising
drugs to at east acutely improve vascular function. Their value for prevention of genomic instability
and vascular aging needs to be assesse . PDE1A and 1C have a putative r le in atherosclerosis,
arteriosclerosis, reduced blood flow and hypertension (see Sections 4.5.1 and 5.4). Their expression is
strongly related to cell lar senesc nc , and genetic variables of the PDE1A gene affect bloo pr ssure
and vascular hypert ophy (Section 4.5.1). Th s, both PDE1 subtypes appear t b central in vascular
aging-related disease. Small, thick arrows pointing up or down indicate up- and down-regulation
respectively. Blunt arrows indicate inhibition, pointed thine arrow indicate stimulation.
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3.5. Cyclin-Dependent Kinase Inhibitor 2 (CDNK2) A and B
Further exploring the role of genomic instability-induced cellular senescence in vascular aging,
gene variations in senescence regulators have been associated with age-related vascular disease
in humans. Several studies have provided insight about the risk association of the 9p21 locus
with aging-related cardiovascular diseases such as atherosclerosis and aortic aneurysm [79]. This
chromosomal region codes for two cyclin-dependent kinase inhibitor genes, CDKN2A, comprising
codes for p16INK4A and p14ARF (p19ARF in mice), and CDKN2B, coding for p15INK4B. These CDKs are
key molecules involved in the regulation of cellular replication, among others in vascular cells [80].
Genetic polymorphisms in this chromosomal region have indicated that 9p21 variation has a significant
influence in the genetic expression of CDKN2A and CDKN2B in VSMCs, which could increase the
susceptibility to CAD [81]. In addition, differential expression of CDNK2A and CDNK2B has been
observed in senescent cells in vitro and in aging tissues of rodents and humans [82]. Thus, the
measurement of the expression of these genes has led to their use as a potential biomarker of biological
age [83]. Most of the studies have determined the role of CDNK2A and CDNK2B in aging by focusing
on human tumors, concluding that the deletion and silencing of the CDKN2A–CDKN2B locus are
among the most frequent genetic events found in human cancer cells [84]. Thus, CDNK2A and B play
a central role in diseases of aging.
4. Genomic Instability as a Causal Factor in Vascular Aging: Evidence from Animal Models
4.1. Telomerase-Deficient (TERC´/´ and TERT´/´) Mice
Telomerase-deficient mouse models have been developed by knocking out TERC, TERC´/´ mice,
or the telomerase reverse transcriptase (TERT´/´ mice). Homozygous TERT´/´ and TERC´/´ mice
display short telomeres and a similar phenotype, but the TERC´/´ mice have been studied more
comprehensively. The telomeres of the TERC´/´ mice shorten at a rate of ~5 kb in every subsequent
generation (G). In conscious TERC´/´ mice, higher systolic blood pressures were observed in mice
from G1 compared with wild-type mice, whereas in G3 mice, both systolic and diastolic blood pressures
were increased compared with wild-type and G1 mice [85]. The differences in blood pressure between
TERC´/´ and wild-type mice appear to be caused by an increased production of endothelin-1 in the
TERC´/´ [85].
4.2. Mouse Models of Genomic Instability Associated with Human Progeria
Different mouse models of WS have been developed with either a complete knockout of the
WRN protein, the transgenic expression of human WRN lacking helicase activity, or the in-frame
deletion of the helicase domain. Depending on the model studied, the extent of the aging phenotype
varies. The models lacking RecQ helicase activity show increased genomic instability and have
increased visceral fat, high fasting triglycerides and cholesterol levels, insulin resistance and
hyperglycemia [86]. Telomere shortening appears to be pivotal in the development of some of these
metabolic changes [87], which are relevant analogues for human cardiovascular risk factors. In these
models no vascular problems were reported, except, perhaps, decreased wound healing, which might
implicate worsened angiogenesis.
A mouse model of HGPS expressing human progerin showed aberrations that were largely
restricted to the vascular system. Recapitulating the vascular phenotype seen in patients with HGPS,
these mice exhibited an increasing loss of VSMCs in the lamina media of large arteries [88]. Those
changes were accompanied by a reduced vasodilator response to the NO donor sodium nitroprusside.
Interestingly, the endothelium is initially undamaged, but with progression of the vessel damage, some
loss in the endothelium is observed in 12-month-old mice [88].
Mice lacking proper function of the versatile DNA repair enzyme ERCC1 show many features
of accelerated aging. Ercc1´/´ mice display a severe aging phenotype featuring frailty, osteoporosis,
neurodegeneration, atrophic epidermis, sarcopenia, liver and kidney dysfunction and bone marrow
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degeneration [89]. Ercc1´/´ mice only live four weeks, while mice with reduced ERCC1 function due
to a combined exon 7 deletion allele and a null allele (Ercc1d/´, Ercc1´/∆7 or Ercc1∆/´) live longer (up to
30 weeks). The Ercc1∆/´ mice are healthy up to an age of eight weeks, when they start developing
a gradual aging phenotype. In our previous study we found that Ercc1∆/´ mice had an increased
systolic blood pressure compared to wild-type mice [38]. They also display a decreased vasodilator
response in their microvasculature [38]. Microvascular function was assessed by hind leg reactive
hyperemia using a laser Doppler technique, which measures superficial resistance vessels and possibly
represents both endothelium-dependent and endothelium-independent relaxations [90–92]. Those
microvascular changes resemble the ones seen in aged rodents as well as in humans, and, strikingly,
these changes in humans are at least partly independent of classical cardiovascular risk factors [90,93].
Another important characteristic of the human vascular aging phenotype that was recapitulated in
the Ercc1∆/´ mice includes greater stiffness, as measured by pressure-diameter relationships in the
carotid arteries [38]. While aortic tissue from Ercc1∆/´ contains increased amounts of senescent cells,
the contribution of cellular senescence to vascular dysfunction remains uncertain [38].
Other genetic models add to the evidence, linking vascular senescence with vascular pathology
and disease. Mice carrying the human XPD R722W mutation, so-called XpdTTD mice, show signs
of accelerated vascular aging. In humans, the mutation in XPD causes trichothiodystrophy (TTD)
which is characterized by postnatal growth failure, UV sensitivity, neurological degeneration, cachexia,
osteoporosis and a shortened life span [94]. The XpdTTD mice show a similar phenotype, but the
onset and severity of progeria is slower compared to Ercc1∆/´ mice. We assessed vascular function
in XpdTTD mice at 26 and 52 weeks and observed significantly reduced vasodilator responses to
acetylcholine in aortic rings at 52 weeks compared to 26-week-old XpdTTD and wild-type mice [38].
4.3. Mitochondrial DNA Maintenance Defects
ApoE-deficient mice lacking protein kinase ATM (ataxia telangiectasia mutated), a protein
pivotal in DNA damage detection, showed accelerated development of atherosclerosis [95]. This was
attributed to increased mtDNA damage leading to malignant metabolic changes. Further exploring
the involvement of DNA (mtDNA), polymerase gamma (POLG) performs DNA synthesis inside the
mitochondria, and thus mutations in POLG cause mitochondrial disorders. A mouse model with an
mtDNA mutator phenotype, conferred by a homozygous mutation in POLG, has been used to study
the role of mitochondrial function and aging. In early adulthood the POLG mutant mice develop many
features of premature aging such as weight loss, reduced subcutaneous fat, kyphosis, osteoporosis,
cardiomyopathy and a reduced life span [96]. Oxidative stress and respiratory chain dysfunction
due to the accumulation of mtDNA point mutations in protein-coding genes of the respiratory chain
complexes are considered to contribute to the premature aging phenotype of the POLG mutator mice.
Using a double POLG/ApoE low-density lipoprotein (LDL) receptor knock-out, it was shown that
instability of mtDNA might contribute to atherosclerosis. POLG´/´/ApoE´/´ mice had increased
atherosclerosis in the brachiocephalic artery and descending aorta as compared to POLG+/+/ApoE´/´
controls. The POLG´/´/ApoE´/´ mice also exhibited reduced body weight, reduced fat mass,
hyperlipidemia and apoptosis of VSMCs [97]. Apart from vascular effects, POLG mutant mice develop
cardiac hypertrophy and dilatation, impairment of systolic and diastolic function, and increased
cardiac fibrosis within 13 months of age [98]. Overexpression of catalase in the mitochondria of these
mice attenuated the malignant cardiac phenotype, providing evidence for the role of oxidative stress
in the development of cardiomyopathy due to mtDNA instability.
4.4. BubR1 Knockout
The spindle assembly checkpoint protein BubR1 has an important role in the maintenance of
genomic stability by ensuring the correct microtubule-kinetochore attachment and segregation of
chromatids during mitosis [99].
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Mice with reduced expression of BubR1 (10% of normal levels) develop progressive aneuploidy
and exhibit a vascular aging phenotype characterized by reduced arterial elasticity, a reduced number
of VSMCs, loss of endothelial-dependent relaxation, and increased production of superoxide anions.
Apart from problems reminiscent of cardiovascular aging, BubR1 mice also show a variety of progeroid
symptoms [100,101]. Also, naturally aged wild-type mice have decreased BubR1 expression in different
tissues, suggesting that BubR1 may be a regulator in normal aging [18,27,100,101]. Clearance of
p16INK4A-positive senescent cells with the INK-ATTAC strategy in BubR1 progeroid mice ameliorates
several of the progeroid hallmarks. However, the cardiovascular problems are not rescued, which
corresponds with the observation that these features are p16INK4A-independent in this model [102].
Importantly, vascular aging in ERCC1-defective mice appears to be associated with p53- and p21Cip1
(or p21Waf1)-related senescence [8,38], and this might further explain the ineffectiveness of removing
p16-positive cells to improve cardiovascular function in BubR1 mice. Interestingly, it was recently
shown that clearance of p16INK4A-positive senescent cells in non-progeroid mice increases the life span
and reduces cardiac stress sensitivity [18,102]. This indicates that cellular senescence is indeed involved
in deleterious cardiovascular phenotypes, involving both p16INK4A as well as p53- and p21-related
senescence in a differential way.
4.5. Vascular Functional/Pharmacological Changes Due to Genomic Instability
4.5.1. NO-cGMP Signaling
NO is a key participant in many physiological pathways such as vasodilation, neurotransmission,
and macrophage-mediated immunity. In the vascular endothelium, NO is produced from the substrate
L-arginine by the enzyme eNOS (or nitric oxide synthase type III). The eNOS is activated by increased
cytoplasmic Ca2+ levels, as induced, among others, by binding of vasodilatory (neuro)hormones to
their G protein-coupled receptors [103]. Evidence provided up to date suggests that there is a reciprocal
relationship between defective eNOS activity and genomic instability. During vascular aging, there is
an increased production of ROS [104]. This ROS can be partly produced by eNOS, when the enzyme is
in a so-called uncoupled state due to a reduced expression of the cofactor tetrahydrobiopterin (BH4),
as has been shown in aging rats [105]. ROS coming from this and other sources, such as nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase or mitochondria, react with NO to form harmful
free radicals, including peroxynitrite (ONOO´) and N2O3. The overproduction of ROS not only leads
to a gradual reduction of NO bioavailability in the vasculature, but in addition can cause single-strand
DNA breaks, 7,8-dihydro-8-oxoguanine and other oxidative lesions [106].
The aberrant eNOS function is closely associated with dysfunction as observed in aged and
diseased blood vessels. In eNOS´/´ mice, systemic hypertension, altered vascular remodeling,
dysfunctional angiogenesis and a prothrombotic phenotype have been observed [107–111]. In human
atherosclerosis, eNOS mRNA expression was shown to be decreased in endothelial cells of advanced
atherosclerotic plaques, which is accompanied by overt DNA damage [36]. In addition, eNOS
uncoupling has been reported in patients with endothelial dysfunction as a consequence of diabetes,
hypertension, hypercholesterolemia and smoking, linking the mechanism to classical risk factors [112].
Apart from a potential role of eNOS dysfunction in the production of DNA lesions, genomic
instability itself causes dysfunction of NO signaling. Organ bath studies and molecular analyses
in Ercc1d/´ mechanistically explained the decreased vasodilator responses [38]. These experiments
showed that NO-mediated responses, eNOS expression, and eNOS activation through phosphorylation
serine 1177 were decreased. Increased generation of ROS, a central mechanism in age-related decreased
NO-dependent vasodilation, was partly responsible for the diminished vasodilation in Ercc1d/´
mice since anti-oxidants such as N-acetylcysteïne and BH4 improved vasodilation [38]. Therefore,
faulty eNOS activation and genomic instability appear to form a vicious circle leading to progressive
endothelial dysfunction and accelerated vascular aging (Figure 3).
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Downstream of NO production, the ERCC1 functional mutation causes a pronounced defect in
cGMP responsiveness. In the vascular function assessment of the Ercc1d/´ mice we found a strong
reduction in the relaxations to the NO donor SNP compared to wild-type mice. The responses were
completely dependent on soluble guanylyl cyclase (sGC) activity. No differences in sGC activity or
protein levels were found between Ercc1d/´ and wild-type mice. When we measured the vasodilator
responses of the aortic rings to SNP in the presence of vinpocetine, a phosphodiesterase (PDE) type
1 inhibitor, or Sildenafil, a PDE5 inhibitor, the dilator responses were increased. However, while
in wild-type mice the greatest improvement was given by Sildenafil, in Ercc1d/´ mice it was given
by vinpocetine [113]. This finding suggests that in Ercc1d/´ mice, a mouse model for accelerated
aging due to genomic instability, PDE1 has a stronger role than PDE5 in regulating cGMP signaling
and vasomotor function [113]; at least, it undergoes stronger regulation, because cellular senescence
was shown to be strongly associated with increased expression of both PDE1A and C subtypes,
and to a lesser extent with PDE5, in human cultured VSMCs. Supportive for a role in humans,
PDE1A gene variations in human cohorts were associated with diastolic blood pressure and intima
media thickness [113]. Together with previous observations showing associations of PDE1C with
atherosclerosis, this places cGMP metabolism alongside these enzymes in the center of human vascular
aging [114,115] (Figure 3).
4.5.2. NF-E2-Related Factor-2 (Nrf2) and Antioxidant Pathways
NF-E2-related factor-2 (Nrf2) is a transcription factor activated in the vasculature to modulate
the up-regulation of antioxidant genes, whose protein products are involved in the clearance of ROS
and electrophilic molecules [116]. Consequently, Nrf2-dependent signaling pathways are activated as
an adaptive mechanism in response to increased production of ROS, attenuating vascular oxidative
stress and the damage caused by several stressors [117–119]. A dysfunction in Nrf2 action increases
age-related cellular oxidative stress and cellular damage in aged vessels [120]. Nrf2 has a reduced
function in senescence, whereas its silencing leads to premature senescence [121]. Remarkably, despite
the fact that Nrf2 deletion leads to slower cell growth and shorter life span of individual cells in murine
embryonic fibroblast cultures, it paradoxically induces immortalization in such cultures due to an early
loss of p53 and p53-dependent gene expression [122]. This shows that Nrf2 loss-of-function has a dual
pro-aging and oncogenic effect, centering the transcription factor in age-related disease. In addition,
the effects of ROS associated with classical risk factors (smoking, hyperglycemia) in cardiomyocytes
and mouse hearts are worsened after depletion of Nrf2, suggesting that Nrf2 protects against cardiac
damage induced by mechanisms that can contribute to genomic instability [117,123–125]. Xpg´/´
and SIRT6´/´ mice, experimental models that exhibit progeroid phenotypes on the basis of genomic
instability, have shown an accelerated cellular senescence, increased ROS levels and dysregulated
redox metabolism. The Nrf2-regulated antioxidant pathways are up-regulated in the cerebellum and
mesenchymal stem cells of these mice [126,127], which illustrates the physiological importance of Nrf2
as a line of defense against genomic instability caused by ROS. Importantly, Nrf2 is also involved in
the regulation of production of NO vs. ROS through its role in eNOS uncoupling and activation [128].
This evidence suggests that Nrf2 provides a protective pathway during genomic instability, although
the specific relation to vascular aging as caused by genomic instability has not been investigated yet.
5. Perspectives
5.1. Directions for Future Studies Establishing the Role of Genomic Instability
Although the evidence summarized above strongly indicates a major role of genomic instability
in vascular aging, important questions remain to be solved. Firstly, there is the question as to
whether the accelerated vascular aging features that are observed are due to local vascular processes,
or whether they are the consequence of the general accelerated deterioration in mouse models
of genomic instability. Tissue-specific inactivation of DNA repair enzymes is a means to explore
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this question. To this end, endothelial cell- and VSMC-specific Cre recombinase strains and mouse
strains with Plox sites in DNA repair genes of interest are available, but still need to be combined.
Furthermore, the mechanisms that are the interface between genomic instability and derailment
of vascular signaling systems need to be resolved. Cellular senescence has been mentioned as an
option, but apoptosis is also a candidate mechanism. The role of cellular senescence vs. vascular cell
apoptosis in vascular aging remains an important question. Although previously discussed mouse
studies provide compelling evidence, the role of cellular senescence in vivo in human aging remains
unclear, mostly due to the absence of specific biomarkers that can provide information about the
state of cells in tissues [129]. Restricting this to vascular aging, no conclusive evidence for a causal
role of cellular senescence in vascular aging, let alone that induced by genomic instability, has been
published yet. The aforementioned results in INK-ATTAC models on a wild-type mouse background,
and in ERCC1-defective mice, are, however, highly indicative [18,38]. Models combining constructs to
eliminate senescent cells in a background of vascular-specific genomic instability are putative tools to
further establish this mechanism.
Another mechanism could be stem cell exhaustion, which requires comprehensive analysis of
vascular cell progenitors in mice with increased genomic instability. In ERCC1-deficient mice, reduced
hematopoietic progenitor cell reserves have been observed [130]. Since hematopoietic cells generate
vascular progenitor cells [131], there is indeed a motive to explore this possibility.
Whether genomic instability in nuclear DNA outside of telomeres mediates vascular dysfunction
through mutations or transcriptional dysfunction as caused by DNA lesions is a most important
question that remains to be explored (Figure 1). Since DNA lesions have been repeatedly reported
(see above), this is a very realistic option.
5.2. Towards New Interventions in Vascular Aging Caused by Genomic Instability
The awareness that genomic instability and cellular senescence arising thereof play a key role in
general and in vascular aging opens new possibilities to prevent age-related cardiovascular disease.
In particular, life-extending therapies that have been identified thus far are candidate interventions
to decelerate vascular aging. In addition, interventions that prevent vascular genomic instability
or readily improve NO-cGMP signaling are eligible for such purposes. We delineate the various
options here.
5.2.1. Mtor, Rapamycin and Autophagy
During aging, increasing dysfunction related to a progressive failure of maintenance and repair
pathways takes place as aberrant macromolecules, dysfunctional organelles and DNA damage may
accumulate in cells and tissues [132]. Therefore, cellular maintenance mechanisms are crucial to
preserve normal cellular functions. Autophagy, one of the main cellular preservation processes,
is involved in the degradation of long-lived proteins and dysfunctional organelles as well as in the
maintenance of the cell in case of failure of macromolecule repair [133]. With age the rate of autophagy
and protein degradation declines [134,135]. Importantly, genetic ablation of Atg7, an important
mediator of autophagy, causes an accelerated appearance of vascular aging hallmarks in mice [136].
Autophagy-modifying drugs, such as rapamycin, inhibit the mammalian target of rapamycin complex
1 (mTORC1) and control the activation of autophagy-related signaling pathways. Rapamycin (also
known as sirolimus) increases longevity and delays pathological lesions in mice [137]. Furthermore,
the therapeutic use of rapamycin or related drugs prevents age-related diseases such as cancer and
cardiovascular diseases in animal models [138,139]. In addition, the pleiotropic anti-atherosclerotic
effects of rapamycin have allowed the implementation of rapamycin-based therapies to prevent
or delay the pathogenesis of atherosclerosis [140]. Further, it has been reported that rapamycin
improves endothelium-dependent vasodilation in old rodents [141]. A potential beneficial effect of
mTOR inhibition on vascular aging independent from autophagy regulation was proposed [142].
This effect would be based on the regulation of a signaling network, consisting of mTOR, adenosine
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monophosphate-activated protein kinase (AMPK), and sirtuin (SIRT)-1. In this model, mTOR inhibition,
in concert with SIRT-1 and AMPK activation, would counteract age-related vascular dysfunction
thanks to modulation of the common transcription factors NFκB, FoxO and p53, that, when integrated,
determine stress resistance, inflammation, ROS production, NO signaling, genomic instability and
cellular senescence. Apart from this link to genomic instability and senescence, it has been found in a
mouse model of Hutchinson-Gilford progeria that AMPK activation and mTOR inhibition occurs in
conjunction with activation of autophagy [143]. Thus, models of genomic instability appear to implicate
the proposed mTOR–AMPK signaling interaction, with a link to the regulation of autophagy (Figure 2).
However, the effect on vascular aging as based on genomic instability remains to be explored.
Discouraging the use of mTOR inhibition is the fact that rapamycin significantly attenuates both
endothelial function and the expression of eNOS in human endothelial cell lines in vitro, although
it does not cause endothelial cell death [144]. Studies with mTOR-inhibiting drugs, among others
applied on coronary stents in patients with advanced arterial aging, have reported deleterious effects
of such drugs on various variables of endothelial (dys)function, although conflicting results are
abundant [145–149]. It is unclear whether the conflicting results are dependent on the concentration of
the mTOR inhibitor to which the endothelial cells are exposed, which presumably is very high in the
case of drug-eluting stents. Although in cultured endothelial cells the increasing anti-inflammatory
effect of increasing concentrations of mTOR inhibitors parallels the increasing cytostatic effect [150],
this issue needs further inspection. We have also shown that rapamycin actually induces PAI-1
expression in cultured endothelial cells and in vivo in mice [151], so the net benefit of this drug in
preventing senescence may be mixed at best.
In summary, mTOR inhibition, on the one hand, seems to be an attractive hypothetical option to
reduce vascular aging in relation to genomic instability, but the idea should be approached cautiously.
5.2.2. Senolytics and Inhibitors of Senescent Cell Signaling
Cellular senescence and the overproduction of SASP-associated proteins, also referred to as the
senescence-messaging secretome (SMS), contributes to local and systemic dysfunction and disease.
Therefore, the implementation of “senolytic” therapies has been approached as an intervention to
specifically target senescent cells (Figure 2), eliminate them, and thus diminish the contribution of
SASP and SMS [152]. The use of senolytic drugs including dasatinib and quercetin has been effective in
eliminating senescent primary mouse embryonic fibroblasts and senescent human fat cell progenitors.
In vivo, the combination of these drugs reduced senescent cells in normal aged, radiation-exposed mice,
and in Ercc1´/∆ mice [152]. In addition, this study showed that periodic drug administration extended
the health span in Ercc1´/∆ mice and delayed age-related symptoms and pathology, osteoporosis,
and loss of intervertebral disc proteoglycans. Despite the evidence suggesting that interventions that
reduce the number of senescent cells could mitigate age-related tissue dysfunction, the burden of cell
senescence biomarkers and SASP needs to be further studied and validated in humans. Therefore, the
implementation of new therapies to reduce senescent cell number and SASP must be characterized.
Pioneer results from our group showed for the first time that modulation of the SMS can actually
prevent the development of senescence in kl/kl mice, a mouse model of accelerated aging [67].
We observed that forced decrease of PAI-1 attenuated levels of the SMS factors insulin-like growth
factor-binding protein 3 (IGFBP3) and interleukin-6 in plasma of kl/kl mice to levels seen in wild-type
(WT) mice. In addition, telomere integrity was partially protected in numerous tissues. Furthermore,
the nuclear accumulation of the senescence marker p16INK4A was prevented. Similar observations
were made in another aging-related model [68]. It is important to note that IGFBP3 is also strongly
affected in DNA repair-defective progeroid models, as are other components of the IGF-1 growth
factor signaling pathway, placing this pathway in the center of genomic instability-related (vascular)
aging [8,153]. Moreover, this link raises the exciting possibility that PAI-1 might be involved in genomic
instability-related vascular aging (Figure 2). As a still remote possibility, PAI-1 might act as part of the
SMS from cells that become senescent due to unrepaired DNA damage, thus transmitting a harmful
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signal to cells in which the genomic integrity is still warranted (Figure 3). Application of genetic or
pharmacological inhibition of PAI-1 in models of genomic instability is therefore an attractive approach
to test this hypothesis.
5.3. Dietary Restriction
In search of treatment perspectives, it is of course important to consider more general anti-aging
and longevity-increasing interventions. Apart from the previously discussed possibility to employ
rapamycin against vascular aging, dietary restriction (DR) is perhaps the most important and
well-known option. DR is a reduction of intake of food to the level that it results in low-normal
levels of energy intake while avoiding malnutrition [154]. Claims of an effect of diet restriction on
longevity date back as far as 3000 years. Studies that have taken place over many decades over the
last century indeed confirm such an effect in various species, including yeast, worms, flies, spiders,
rotifers, fish and rodents, demonstrating that DR is the most effective intervention to slow down aging
and extend life expectancy [155–161].
DR is known also to protect against age-related cardiovascular disease. Two main mechanisms
can be involved: (1) reduction of the intake of harmful food, such as carbohydrates and polysaturated
fats [162,163]; or (2) slowing down of the aging process itself. It has been shown that chronic
DR improves the aging-related rise of blood pressure and vascular wall remodeling, as shown
in rodents [164,165]. This effect can be attributed to the improvement of vascular relaxation, a
consequence of decreased ROS and increased NO bioavailability. In addition, DR has been reported to
attenuate cardiovascular disease in nonhuman primates [74,166].
It is not clear what the main mechanisms of the anti-aging effect of DR are. However, the
reduction of genomic instability is a possibility. In a previous review [8] we discussed that effects on
oxidative stress-induced DNA and macromolecular damage are a putative mechanism. Reports have
shown a possible effect of specific nutrient restriction and of caloric restriction on markers of DNA
damage and DNA repair capacity, and a plethora of publications regarding the association between
food consumption and telomere length is available [167–170]. This observation pleads for evaluation
of the effects of DR on the general and vascular aspects of aging in models of genomic instability.
Alternatively, effects on IGF-1/growth hormone (GH) signaling, SIRT-1 and nutrient-sensing pathways
might be at play [8] (Figure 2). Since IGF-1/GH signaling is suppressed both after DR and in
mouse models of genomic instability, this pathway apparently shares a common function in DR
and the survival response in progeroid mice. Mouse models in which GH signaling is intentionally
knocked out display increased longevity, and share features of the genetic program with genomic
instability models [153]. Therefore, IGF-1/GH suppression is a point of convergence between DR,
genomic instability and longevity. Whether this convergence takes place after genomic instability to
improve survival, contributes to improved genomic integrity, as proposed above, or both remains to
be elucidated. The effect of dietary restriction therefore needs to be explored in models of genomic
instability, importantly those involving evaluation of vascular aging. The role of altered GH vs.
IGF-1/insulin therein on vascular function needs special attention as these pathways appear to have
opposite effects, as previously explained [8].
We here propose that the aforementioned relationship with mTOR and AMPK might also be
important in DR effects (Figure 2). There is evidence that DR deactivates the mTOR-dependent
signaling pathways, slowing aging and delaying aging-related diseases [171]. This suggests that DR
and rapamycin can act together but have different effects on several pathways related to an increased
longevity in young mice; therefore, the combination of both therapies could cause and exponential rise
of lifespan in mice [172]. It would be interesting to investigate if such an interaction also exists for the
attenuation of vascular aging.
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5.4. PDE Inhibition
As mentioned before, there appears to be a pivotal role in vascular aging for PDE1 (Figure 3),
and possibly also PDE5 [113]. At least, the inhibition of both PDE subtypes can acutely counteract
diminished vasodilator responses caused by genomic instability [113]. Whether chronic treatment
will also slow down vascular aging remains to be explored. An attractive aspect of PDE1 and
5 as drug targets is that there are several experimental and clinically approved drug candidates
that might overcome the increased PDE activity. One is the selective PDE1 inhibitor IC86340, but
unfortunately this drug appears not to be available anymore [173,174]. Other PDE1 inhibitors are
under development [175]. Further, there is the possibility to inhibit PDE5, or both PDE1 and 5.
Sildenafil is a PDE5 inhibitor which also blocks PDE1 at high doses [176]. Sildenafil was found to
reduce both diastolic and systolic blood pressure in untreated hypertensive patients. However, due
to Sildenafil’s short duration of action, research is focusing on new inhibitors such as tadalafil [177].
Vinpocetine is a PDE inhibitor with a preferential affinity for PDE1 over PDE5. Vinpocetine is an Food
and Drug Adminstration (FDA)-approved nutriceutical and a registered drug in Eastern Europe, used
to enhance cerebral bloodflow and improve memory [178]. PDE1 inhibitors were also developed for
the treatment of cognitive impairment associated with schizophrenia [175]. Such treatment inhibits
injury-induced hypertrophy in human and rodent vessels, and decreases atherosclerosis in ApoE
knockout mice [179,180]. Therefore PDE1 inhibition is an attractive option for treating age-associated
cardiovascular diseases. Until now, vinpocetine never found widespread application, for reasons that
are unclear.
5.5. Reconsideration of Antioxidant Therapies
As explained above, ROS have been identified as a source of DNA damage, and therefore ROS
scavenging is a potential treatment modality. Clinical studies applying ROS scavengers (antioxidants)
have, however, not resulted in benefits for patients suffering from cardiovascular diseases [181].
Although this might be due to the fact that such interventions might require the onset of intervention
early in life, there is also a shortcoming in that the drugs might not reach the right place at the right
time or even hamper healthy cellular signaling that is performed by ROS [182]. A better targeted
interaction of antioxidant enzymes and ROS might overcome the latter shortcomings of exogenously
applied ROS scavengers.
Nrf2 has been proposed as a “master regulator” of cytoprotective mechanisms and it could be
associated with increased longevity and attenuating age-related diseases in mice [183]. Therefore, Nrf2
gene regulation and the enhancement of the endogenous antioxidant capacity (Figure 2) could be an
important therapeutic target to diminish the production of ROS, reducing DNA damage and their
effects on vascular aging. Certainly, several drugs have been developed and tested to stimulate the
bioavailability of NO through the regulation of the Nrf2/antioxidant response element (Nrf2/ARE).
The combined action of NO and Nrf2/ARE signaling could improve vascular function and confer
protection against vascular diseases [184]. On the other hand, several alternatives to increase Nrf2
have been currently explored, including calorie restriction, ozone therapy, hyperbaric oxygen and
physical exercise [185].
6. Summary
There is ample evidence that genomic instability is involved in vascular aging. Nuclear DNA
lesions, among which is telomere erosion, and mitochondrial DNA damage are strongly associated
with several main features of vascular aging, such as diminished vasodilator capacity and increased
vasoconstriction, increased blood pressure, increased vascular stiffness and atherosclerosis. Pivotal
cellular biological changes involved in these pathological features comprise cellular senescence,
apoptosis, autophagy, stem cell exhaustion and altered proliferative capacity of vascular cells.
The role of gene mutation and of compromised transcription remains unknown (Figure 1). Potential
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mediating signaling pathways involved include components of the survival response (Figure 1),
notably antioxidants under regulation of Nrf2 (beneficial), increased inflammatory status (detrimental)
and decreased IGF-1/GH signaling (detrimental), as well as the interplay between mTOR, AMPK and
NFκB, SIRT-1, and PAI-1, p53- and p21- and p16-related signaling. Proposed remedies against genomic
instability-related vascular aging include PAI-1 inhibition, mTOR inhibition, DR, senolytics, PDE1 and
5 inhibitors and stimulators of Nrf2.
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